Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: Correlation with histopathologic effects and biochemical recurrence

Urology

Volumn 63, Issue 6, 2004, Pages 1184-1190

  Miyata, Yasuyoshi ^a   Sakai, Hideki ^b   Kanda, Shigeru ^b   Igawa, Tsukasa ^b   Hayashi, Tomayoshi ^b   Kanetake, Hiroshi ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; LUTEINIZING HORMONE ANTIBODY; SOMATOMEDIN BINDING PROTEIN 3;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; STANDARDIZATION;

AGED; ANDROGEN ANTAGONISTS; APOPTOSIS; CHEMOTHERAPY, ADJUVANT; CYTOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 2942583126     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.02.015     Document Type: Article

References (33)

1. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins biological actions. Endocr Rev. 16:1995;3-34
2. Khandwala H.M., McCutheon L.E., Flyvbjerg A., et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 21:2000;215-244
3. Chan J.M., Stampfer M.J., Giovannucci E.G., et al. Plasma insulin-like growth factor-I and prostate cancer risk a prospective study. Science. 279:1998;563-566
4. O'Brien M.F., Watson R.W., Fitzpatrick J.M. Insulin-like growth factor I and prostate cancer. Urology. 58:2001;1-7
5. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 20:1999;761-787
6. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins biological actions. Endocr Rev. 16:1995;3-34
7. Byrne C., Colditz G.A., Willett W.C., et al. Plasma insulin-like growth factor (IGF) 1, IGF-binding protein 3, and mammographic density. Cancer Res. 60:2000;3744-3748
8. Zhao H., Grossman H.B., Spitz M.R., et al. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 169:2003;714-717
9. Chokkalingam A.P., Pollak M., Fillmore C.-M., et al. Insulin-like growth factors and prostate cancer a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 10:2001;421-427
10. Rajah R., Valentinis B., Cohen P. Insulin-like growth factor binding protein-3 induced apoptosis and mediates the effect of transforming growth factor-β on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 272:1997;12181-12188
11. Rajah R., Khare A., Lee P.D., et al. Insulin-like growth factor-binding protein-3 is partially responsible for high-serum-induced apoptosis in PC-3 prostate cancer cells. J Endocrinol. 163:1999;487-494
12. Kaicer E., Blat C., Imbenotte J., et al. IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC-3) - differential effect on PC-3 and normal prostate cell growth. Growth Regul. 3:1993;180-189
13. Oh Y., Muller H.L., Lamson G., et al. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem. 268:1993;14964-14971
14. London S.J., Yuan J.-M., Travlos G.S., et al. Insulin-like growth factor I, IGF-binding protein 3 and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst. 94:2002;749-754
15. Katsaros D., Yu H., Levesque M.A., et al. IGFBP-3 in epithelial ovarian carcinoma and its association with clinicopathological features and patient survival. Eur J Cancer. 37:2001;478-485
16. Miyata Y., Sakai H., Hayashi T., et al. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate. 54:2003;125-132
17. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 92:2000;1472-1489
18. Shariat S.F., Lamb D.J., Kattan M.W., et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 20:2002;833-841
19. Tricoli J.V., Winter D.L., Hanlon A.L., et al. Radical differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology. 54:1999;178-182
20. Tennant M., Thrasher J., Twomey P., et al. Insulin-like growth factor-binding protein-2 and -3 expression in benign human epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 81:1996;411-420
21. Thrasher J., Tennant M., Twomey P., et al. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue clinical correlation. J Urol. 155:1996;999-1003
22. Hampel O.Z., Kattan M.W., Yang G., et al. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma a prognostic study. J Urol. 159:1998;2220-2225
23. Nickerson T., Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology. 54:1999;1120-1125
24. Huynh H., Pollak M., Zhang J.C. Regulation of insulin-like growth factor (IGF) II and IGF binding protein-3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1, 25(OH)(2)D-3 and its analog EB1089. Int J Oncol. 13:1998;137-143
25. Nickerson T., Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding protein-3. J Endocrinol. 160:1999;223-229
26. Zi X., Zhang J., Agarwal R., et al. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res. 60:2000;5617-5620
27. Miyata Y., Koga S., Kanda S., et al. Expression of cyclooxygenase-2 in renal cell carcinoma correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res. 9:2003;1741-1749
28. International Union Against Cancer. TNM Classification of Malignant Tumors. 5th ed. 1997;Wiley-Liss, New York
29. Szende B., Romics I., Vass L. Apoptosis in prostate cancer after hormonal treatment. Lancet. 342:1993;1422
30. Szende B., Romics I., Minik K., et al. Repeated biopsies in evaluation of therapeutic effect in prostate carcinoma. Prostate. 49:2001;93-100
31. Stattin P., Westin P., Damber J.E., et al. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer. 77:1998;670-675
32. Tapia-Vieyra J.V., Mas-Oliva J. Apoptosis and cell death channel in prostate cancer. Arch Med Res. 32:2001;175-185
33. Tang D.G., Porter A.T. Target to apoptosis a hopeful weapon for prostate cancer. Prostate. 32:1997;284-293